Skip to main content
Erschienen in: Virchows Archiv 5/2016

16.03.2016 | Original Article

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma

verfasst von: Pekka Peroja, Kirsi-Maria Haapasaari, Susanna Mannisto, Ilkka Miinalainen, Petri Koivunen, Sirpa Leppä, Marja-Liisa Karjalainen-Lindsberg, Milla Elvi Linnea Kuusisto, Taina Turpeenniemi-Hujanen, Outi Kuittinen, Peeter Karihtala

Erschienen in: Virchows Archiv | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Redox state-regulating enzymes may have roles in chemoresistance and also in lymphomagenesis, but there have been only a limited number of studies on this topic in lymphomas. Our aim was to assess expression of the redox state-regulating enzymes peroxiredoxins (Prxs) I–VI and thioredoxin (Trx) and the oxidative stress marker nitrotyrosine in follicular lymphomas (FLs). We immunohistochemically assessed Prxs I–VI, Trx and nitrotyrosine in a cohort of 76 histologically confirmed, untreated FLs. We also studied the localisation of Prxs I, II, III, V and VI by means of immunoelectron microscopy (IEM). Immunohistochemistry results were correlated with disease-specific survival (DSS), progression-free survival (PFS), overall survival (OS) and clinical prognostic factors. When all Prx expression intensities were grouped as a single variable, we discovered that high total Prx intensity correlated with favourable DSS (p = 0.024) and OS (p = 0.035) but not with PFS. No deaths due to lymphoma were recorded amongst patients with high total Prx expression during the median follow-up period of 7.6 years. IEM results were in line with earlier ones demonstrating wide subcellular localisation of Prx isoenzymes. In conclusion, our results demonstrate an association between high total Prx expression and prolonged survival and suggest that Prxs may have a protective role in FL that cannot be compensated by other antioxidant mechanisms.
Literatur
1.
Zurück zum Zitat Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR (2013) Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. doi:10.1093/annonc/mds429 PubMed Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR (2013) Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. doi:10.​1093/​annonc/​mds429 PubMed
2.
Zurück zum Zitat Yamamoto E, Tomita N, Sakata S, Tsuyama N, Takeuchi K, Nakajima Y, Miyashita K, Tachibana T, Takasaki H, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Harano H, Motomura S, Ishigatsubo Y (2013) MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy. Cancer Sci. doi:10.1111/cas.12288 Yamamoto E, Tomita N, Sakata S, Tsuyama N, Takeuchi K, Nakajima Y, Miyashita K, Tachibana T, Takasaki H, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Harano H, Motomura S, Ishigatsubo Y (2013) MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy. Cancer Sci. doi:10.​1111/​cas.​12288
3.
Zurück zum Zitat Wood B, Sikdar S, Choi SJ, Virk S, Alhejaily A, Baetz T, LeBrun DP (2013) Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease. Leuk Lymphoma. doi:10.3109/10428194.2012.742522 PubMed Wood B, Sikdar S, Choi SJ, Virk S, Alhejaily A, Baetz T, LeBrun DP (2013) Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease. Leuk Lymphoma. doi:10.​3109/​10428194.​2012.​742522 PubMed
4.
Zurück zum Zitat Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Huang HQ, Lin TY, Xia ZJ, Li S, Li ZM (2012) Expression of BAFF and BAFF-R in follicular lymphoma: correlation with clinicopathologic characteristics and survival outcomes. PLoS ONE. doi:10.1371/journal.pone.0050936 Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Huang HQ, Lin TY, Xia ZJ, Li S, Li ZM (2012) Expression of BAFF and BAFF-R in follicular lymphoma: correlation with clinicopathologic characteristics and survival outcomes. PLoS ONE. doi:10.​1371/​journal.​pone.​0050936
7.
Zurück zum Zitat Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y (2002) Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196:316–323CrossRefPubMed Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y (2002) Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196:316–323CrossRefPubMed
8.
9.
Zurück zum Zitat Lu W, Fu Z, Wang H, Feng J, Wei J, Guo J (2014) Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells’ survival by protecting cells from oxidative stress. Mol Cell Biochem 387(1–2):261–270CrossRefPubMed Lu W, Fu Z, Wang H, Feng J, Wei J, Guo J (2014) Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells’ survival by protecting cells from oxidative stress. Mol Cell Biochem 387(1–2):261–270CrossRefPubMed
10.
Zurück zum Zitat Demasi AP, Martinez EF, Napimoga MH, Freitas LL, Vassallo J, Duarte AS, Soares AB, Araujo NS, Araujo VC (2013) Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation. Virchows Arch. doi:10.1007/s00428-013-1433-1 PubMed Demasi AP, Martinez EF, Napimoga MH, Freitas LL, Vassallo J, Duarte AS, Soares AB, Araujo NS, Araujo VC (2013) Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation. Virchows Arch. doi:10.​1007/​s00428-013-1433-1 PubMed
11.
Zurück zum Zitat Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K, Koivunen P, Sormunen R, Soini Y, Karihtala P (2014) Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology 65:319–327CrossRefPubMed Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K, Koivunen P, Sormunen R, Soini Y, Karihtala P (2014) Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology 65:319–327CrossRefPubMed
12.
Zurück zum Zitat Kuusisto ME, Haapasaari KM, Turpeenniemi-Hujanen T, Jantunen E, Soini Y, Peroja P, Bloigu R, Karihtala P, Kuittinen O (2015) High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of international prognostic index. J Clin Pathol 68:552–556CrossRefPubMed Kuusisto ME, Haapasaari KM, Turpeenniemi-Hujanen T, Jantunen E, Soini Y, Peroja P, Bloigu R, Karihtala P, Kuittinen O (2015) High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of international prognostic index. J Clin Pathol 68:552–556CrossRefPubMed
13.
Zurück zum Zitat Murata M, Kawanishi S (2004) Oxidative DNA damage induced by nitrotyrosine, a biomarker of inflammation. Biochem Biophys Res Commun 316:123–128CrossRefPubMed Murata M, Kawanishi S (2004) Oxidative DNA damage induced by nitrotyrosine, a biomarker of inflammation. Biochem Biophys Res Commun 316:123–128CrossRefPubMed
14.
Zurück zum Zitat Peroja P, Pasanen AK, Haapasaari KM, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, Bloigu R, Lilja L, Kuittinen O, Karihtala P (2012) Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Exp Hematol Oncol 1:2–3619-1-2CrossRefPubMedPubMedCentral Peroja P, Pasanen AK, Haapasaari KM, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, Bloigu R, Lilja L, Kuittinen O, Karihtala P (2012) Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Exp Hematol Oncol 1:2–3619-1-2CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Pasanen AK, Kuitunen H, Haapasaari KM, Karihtala P, Kyllonen H, Soini Y, Turpeenniemi-Hujanen T, Kuittinen O (2012) Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas. Leuk Lymphoma. doi:10.3109/10428194.2011.624226 PubMed Pasanen AK, Kuitunen H, Haapasaari KM, Karihtala P, Kyllonen H, Soini Y, Turpeenniemi-Hujanen T, Kuittinen O (2012) Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas. Leuk Lymphoma. doi:10.​3109/​10428194.​2011.​624226 PubMed
16.
Zurück zum Zitat Slot JW, Geuze HJ (1985) A new method of preparing gold probes for multiple-labeling cytochemistry. Eur J Cell Biol 38:87–93PubMed Slot JW, Geuze HJ (1985) A new method of preparing gold probes for multiple-labeling cytochemistry. Eur J Cell Biol 38:87–93PubMed
17.
Zurück zum Zitat Rani V, Neumann CA, Shao C, Tischfield JA (2012) Prdx1 deficiency in mice promotes tissue specific loss of heterozygosity mediated by deficiency in DNA repair and increased oxidative stress. Mutat Res 735:39–45CrossRefPubMedPubMedCentral Rani V, Neumann CA, Shao C, Tischfield JA (2012) Prdx1 deficiency in mice promotes tissue specific loss of heterozygosity mediated by deficiency in DNA repair and increased oxidative stress. Mutat Res 735:39–45CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA (2009) Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. doi:10.1038/emboj.2009.101 Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA (2009) Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. doi:10.​1038/​emboj.​2009.​101
19.
Zurück zum Zitat Han YH, Kim HS, Kim JM, Kim SK, Yu DY, Moon EY (2005) Inhibitory role of peroxiredoxin II (Prx II) on cellular senescence. FEBS Lett 579:4897–4902CrossRefPubMed Han YH, Kim HS, Kim JM, Kim SK, Yu DY, Moon EY (2005) Inhibitory role of peroxiredoxin II (Prx II) on cellular senescence. FEBS Lett 579:4897–4902CrossRefPubMed
20.
Zurück zum Zitat Kubota D, Mukaihara K, Yoshida A, Tsuda H, Kawai A, Kondo T (2013) Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteome. doi:10.1016/j.jprot.2013.07.022 Kubota D, Mukaihara K, Yoshida A, Tsuda H, Kawai A, Kondo T (2013) Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteome. doi:10.​1016/​j.​jprot.​2013.​07.​022
21.
Zurück zum Zitat Suenaga S, Kuramitsu Y, Wang Y, Baron B, Kitagawa T, Akada J, Tokuda K, Kaino S, Maehara S, Maehara Y, Sakaida I, Nakamura K (2013) Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. Anticancer Res 33(11):4821–4826PubMed Suenaga S, Kuramitsu Y, Wang Y, Baron B, Kitagawa T, Akada J, Tokuda K, Kaino S, Maehara S, Maehara Y, Sakaida I, Nakamura K (2013) Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. Anticancer Res 33(11):4821–4826PubMed
22.
Zurück zum Zitat Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, Xu GL, Ma JL, Zhong W, Jia WD (2014) Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. doi:10.1007/s12032-013-0786-2 Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, Xu GL, Ma JL, Zhong W, Jia WD (2014) Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. doi:10.​1007/​s12032-013-0786-2
23.
Zurück zum Zitat Kalinina EV, Berezov TT, Shtil’ AA, Chernov NN, Glazunova VA, Novichkova MD, Nurmuradov NK (2012) Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med 153(6):879–882CrossRef Kalinina EV, Berezov TT, Shtil’ AA, Chernov NN, Glazunova VA, Novichkova MD, Nurmuradov NK (2012) Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med 153(6):879–882CrossRef
24.
Zurück zum Zitat He T, Banach-Latapy A, Vernis L, Dardalhon M, Chanet R, Huang ME (2013) Peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. Carcinogenesis. doi:10.1093/carcin/bgs389 He T, Banach-Latapy A, Vernis L, Dardalhon M, Chanet R, Huang ME (2013) Peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. Carcinogenesis. doi:10.​1093/​carcin/​bgs389
26.
Zurück zum Zitat Nicolussi A, D’Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi F, Giannini G, Coppa A (2014) PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms. Int J Oncol. doi:10.3892/ijo.2013.2208 PubMed Nicolussi A, D’Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi F, Giannini G, Coppa A (2014) PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms. Int J Oncol. doi:10.​3892/​ijo.​2013.​2208 PubMed
Metadaten
Titel
Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma
verfasst von
Pekka Peroja
Kirsi-Maria Haapasaari
Susanna Mannisto
Ilkka Miinalainen
Petri Koivunen
Sirpa Leppä
Marja-Liisa Karjalainen-Lindsberg
Milla Elvi Linnea Kuusisto
Taina Turpeenniemi-Hujanen
Outi Kuittinen
Peeter Karihtala
Publikationsdatum
16.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 5/2016
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-016-1920-2

Weitere Artikel der Ausgabe 5/2016

Virchows Archiv 5/2016 Zur Ausgabe

Editorial

In this issue

Neu im Fachgebiet Pathologie